about
Identification of novel Mycobacterium tuberculosis CD4 T-cell antigens via high throughput proteome screening.Analyses of the specificity of CD4 T cells during the primary immune response to influenza virus reveals dramatic MHC-linked asymmetries in reactivity to individual viral proteins.Influence of HLA-DRB1 and HLA-DQB1 alleles on IgG antibody response to the P. vivax MSP-1, MSP-3α and MSP-9 in individuals from Brazilian endemic area.T cell antigen discovery using soluble vaccinia proteome reveals recognition of antigens with both virion and nonvirion association.Immunization with apoptotic phagocytes containing Histoplasma capsulatum activates functional CD8(+) T cells to protect against histoplasmosisDevelopment and validation of an epitope prediction tool for swine (PigMatrix) based on the pocket profile methodIn silico design of a DNA-based HIV-1 multi-epitope vaccine for Chinese populations.NOG-hIL-4-Tg, a new humanized mouse model for producing tumor antigen-specific IgG antibody by peptide vaccination.CD4+ T cells provide intermolecular help to generate robust antibody responses in vaccinia virus-vaccinated humans.What Is Known about the Immune Response Induced by Plasmodium vivax Malaria Vaccine Candidates?Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon?Computer-Aided Design of an Epitope-Based Vaccine against Epstein-Barr Virus.Validation of statistical imputation of allele-level multilocus phased genotypes from ambiguous HLA assignments.High-Resolution HLA-A Typing in Normal Iranian PopulationThe in Vitro Antigenicity of Plasmodium vivax Rhoptry Neck Protein 2 (PvRON2) B- and T-Epitopes Selected by HLA-DRB1 Binding Profile.Plasmodium vivax Pv12 B-cell epitopes and HLA-DRβ1*-dependent T-cell epitopes in vitro antigenicity
P2860
Q27303136-91BC45E7-89E2-4A8D-9810-7D4A639F0315Q33905228-CE9BFA3E-2001-4365-A4C0-61AA5426DB09Q34287358-79CBAB9E-C146-4CF8-8A8A-22BE452053E3Q35206861-31C2E746-985F-4622-88EF-373D28E46BFFQ35671601-9A79E503-F35B-470A-AACA-6A6F5006D744Q35775321-66D42546-329E-4DED-BB91-7A00627D5C65Q35887235-3DDBB443-D93A-4E7E-898C-8B496E9D8B49Q36406293-C6556001-4C6A-4383-8BC2-E55D2DBE6DC6Q36920299-79D82B24-82DE-4128-B2FE-1E2BDE441A58Q37638131-B84138DB-9F23-4271-B36F-472BBB3CF9DEQ42361533-DA214AB9-DAB3-421B-AFF2-4BDDB03474EAQ44549769-AB778562-DB4E-4AD3-A2AA-6002123267F2Q46228816-1D8D52FD-4FD5-4573-8992-E94553D677FCQ49794229-09673F2A-6C58-4840-8FD6-47898A6BCB9AQ55380572-C469A26E-1669-4014-9C1D-A30114E56074Q58756533-31771BC0-06A6-45FF-8D7E-DD9889C1DC80
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
HLA-DR: molecular insights and vaccine design.
@ast
HLA-DR: molecular insights and vaccine design.
@en
type
label
HLA-DR: molecular insights and vaccine design.
@ast
HLA-DR: molecular insights and vaccine design.
@en
prefLabel
HLA-DR: molecular insights and vaccine design.
@ast
HLA-DR: molecular insights and vaccine design.
@en
P2860
P1476
HLA-DR: molecular insights and vaccine design.
@en
P2093
J Mauricio Calvo-Calle
Lawrence J Stern
P2860
P304
P356
10.2174/138161209789105171
P577
2009-01-01T00:00:00Z